Canadian medical device company Synaptive Medical has received strategic investment from equity firm General Atlantic.

This will help Synaptive to accelerate commercialisation of its BrightMatter suite of products.

The investment is also expected to assist Synaptive in new research and product development.

The BrightMatter products are designed to provide advanced visual and information tools to enable surgeons to focus on patient outcomes.

Synaptive Medical president Cameron Piron said: “The healthcare industry is shifting toward an integrated delivery model that treats the whole patient from the diagnosis to surgery and beyond.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Efficient medical imaging, combined with timely and effective care, is a critical driver of that change.

"Synaptive is developing novel imaging solutions that will help improve clinical outcomes for patients in partnership with the people and institutions that care for them.

“Partnering with an outstanding investor such as General Atlantic demonstrates our commitment to long-term growth.

"We look forward to leveraging GA’s deep healthcare expertise and strong track record backing high-growth companies.”

Synaptive has cleared its products for clinical use through the review processes of the US Food and Drug Administration (FDA) and Health Canada, beginning with BrightMatter Plan, its surgical planning tool, which secured approval in early 2014 and continuing with approval of more complex surgical navigation and visualization systems.

In four years, Synaptive has introduced five Class-II and three Class-I medical devices in the US and an equivalent number of products in Canada.

"Efficient medical imaging, combined with timely and effective care, is a critical driver of that change."

ImageDrive, Synaptive’s flagship informatics platform, received FDA approval in early 2016.

Synaptive acquired intellectual property and products from ClearCanvas, a developer of innovative imaging informatics solutions last year.

ClearCanvas technology is the architectural backbone for Synaptive’s BrightMatter products, including BrightMatter Plan, and currently has approximately 60,000 worldwide users.


Image: Some of Synaptive’s BrightMatter products. Photo: © Synaptive Medical.